Generalized Myasthenia Gravis clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.
Orange, California and other locations